← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV30행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCLimited DatastalePhase 1
Expansion (BAY94-9343, BAY94-9343 (Expansion))
Bayer·Oncology
127 trials
Overview
Program
BAY94-9343 (Expansion)
Overview
Company
Bayer
Overview
Modality
ADC
Overview
Target
Oncology
Overview
Indication
Oncology
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Technology
Linker
linker length, conferred markedly enhanced binding affinity and avidity compared to th
MoA
Mechanism
and potential as a precision immunomodulator that can selectively expand and reprogram T cells
MoA
Biomarker
biomarkers, neurophysiological function, bladder outcomes and spinal cord imaging metrics
PK/PD
Species
Mouse, Rat
PK/PD
Animal (cat.)
Mouse, Rat, In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Mouse, Rat
Toxicology
Animal (cat.)
Mouse, Rat, In vitro
Toxicology
Major finding
From Fenton reaction to ferroptosis: chemistry of metal complexes in regulated cell death by lipid peroxidation.. Ferroptosis is a regulated, iron-dependent form of cell death characterized by the unchecked peroxidation of polyunsaturated phospholipids and the collapse of cellular antioxidant defenses. Its therapeutic modulation has emerged as a promising strategy across a broad spectrum of diseas…
Toxicology
CRS
Reported
Clinical
Safety signal
From Fenton reaction to ferroptosis: chemistry of metal complexes in regulated cell death by lipid peroxidation.. Ferroptosis is a regulated, iron-dependent form of cell death characterized by the unchecked peroxidation of polyunsaturated phospholipids and the collapse of cellular antioxidant defenses. Its therapeutic modulation has emerged as a promising strategy across a broad spectrum of diseas…
Clinical
Selected reported efficacy
ORR 50%
Clinical
Reported ORR
50%
Clinical
Reported PFS
5.3
Clinical
Reported OS
8.7
Clinical
Result source
ClinicalTrials.gov NCT04447027
Clinical
Program phase
PHASE_1
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT04447027
BAY94-9343 (Expansion) 비교 | 바이오정보모아